Stock listing

OTC:RICFY Recordati S.p.A. Stock

US listing (OTC) of Recordati S.p.A. · home listing Milan:REC

Follow Recordati S.p.A. into a list and get an email when it puts out news.

Share price · OTC:RICFY

$14.11 USD -0.45 (-3.1%)

Close on Oct 27, 2026

Day range
$14.11 – $14.11 USDOct 27, 2026
Volume
455 sharesOct 27, 2026
Market cap
$11.74B USDAt the close on Oct 27, 2026 · price × 832.0M shares outstanding
Recordati S.p.A. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
OTC:RICFY$14.11 USD-0.449 (-3.1%)455$14.11$14.11$14.11$14.55Close on Oct 27, 2026
Frankfurt:RER1€52.90 EUR0.00 (0.0%)—€52.60€52.90€52.60€52.90Close on Oct 30, 2026
Ticker
OTC:RICFY
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
OTC
Currency
USD

What changed lately

Calls

Replays

  • Recordati (Milan:REC) Q2 2026 Earnings Call

    Wed, Jul 29, 2026 · 8:00 AM ET

    Watch Transcript

  • Recordati (Milan:REC) Q1 2026 Earnings Call

    Wed, May 13, 2026 · 8:00 AM ET

    Watch Transcript

  • Recordati (Milan:REC) Q4 2025 Earnings Call

    Wed, Feb 18, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Recordati announces the winner of the 12th edition of the Arrigo Recordati Prize for scientific research

Sep 17, 2026

Palliser Capital Issues Letter to Recordati’s Board of Directors Urging Withdrawal of Support on Materially Undervalued Tender Offer

Sep 14, 2026

Recordati: solid momentum of the group continues first half 2026. net revenue +6.6%, EBITDA +8.8%, Adjusted Net income +6.7%

Jul 28, 2026

Recordati celebrates its first 100 years at triennale milano with an exhibition revealing objects and images from its historical archive for the first time

Jun 16, 2026

First Quarter Report 2026

May 14, 2026

Recordati: strong momentum of the group continues into the first quarter of 2026 net revenue +4.9%, EBITDA(1) +5.0%, Adjusted net income(2) +7.2%

May 12, 2026

1 April 2026 - Financial Statements of Recordati S.p.A. at 31 December 2025 and related Report of the Auditing Firm

Apr 1, 2026

Recordati reports strong preliminary full year 2025 results: revenue +11.8%, EBITDA(1) +14.5%, Adjusted net income(2) +14.5%

Feb 17, 2026

Recordati reports strong preliminary full year 2025 results: revenue 11.8%, EBITDA 14.5%, Adjusted net income 14.5%

Feb 17, 2026

Recordati announces strategic collaboration with Moderna to develop and commercialize worldwide mRNA 3927 for the treatment of propionic acidemia

Jan 29, 2026

All Recordati S.p.A. news

Decks

Recordati S.p.A. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
12 in the last 12 months · 14 in all · newest Sep 17, 2026 · oldest 2025
Calls
22 calls with a replay · 22 with a transcript · latest Jul 29, 2026
Decks
140 decks · latest Jul 29, 2026

Where Recordati S.p.A. is listed

ListingExchangeCountryCurrency
Milan:REC · Home listingMilanItalyEUR
OTC:RICFY · This pageOTCUnited StatesUSD
gettex:RER1gettexGermanyEUR
VIE:RECViennaAustriaEUR
OTC:RCDTFOTCUnited StatesUSD
Tradegate:RER1TradegateGermanyEUR
LS Exchange:A0EABRLS ExchangeGermanyEUR
Turquoise:RECMTurquoiseUnited KingdomEUR
Lang & Schwarz:A0EABRLang & SchwarzGermanyEUR
LSIN:0KBSLSINUnited KingdomEUR
Aquis:RECMAquisUnited KingdomEUR
BMV:RECNBMVMexicoMXN
Aquis:RECMAquisUnited KingdomEUR
Stuttgart:RER1StuttgartGermanyEUR
Frankfurt:RER1FrankfurtGermanyEUR
Hanover:RER1HanoverGermanyEUR
BIVA:RECNBIVAMexicoMXN
Dusseldorf:RER1DusseldorfGermanyEUR
Hamburg:RER1HamburgGermanyEUR
Munich:RER1MunichGermanyEUR

Log in to ask 6ix AI your own questions about Recordati S.p.A.